Discovery of novel compounds as potent activators of Sirt3.

Activity tests Affinity tests DNA encoded Library Docking studies Drug discovery High throughput Screening Sirtuin Sirtuin-3

Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 11 2022
Historique:
received: 04 01 2022
revised: 14 08 2022
accepted: 01 09 2022
pubmed: 4 10 2022
medline: 18 10 2022
entrez: 3 10 2022
Statut: ppublish

Résumé

Among the sirtuin enzymes, Sirt3 is one of the most important deacetylases as it regulates acetylation levels in mitochondria, which are linked to the metabolism of multiple organs and therefore involved in many types of age-related human diseases such as cancer, heart diseases and metabolic diseases. Given the dearth of direct activators of Sirt3, the identification of new modulators could be a key step in the development of new therapeutics. Here we report the discovery of Sirt3 modulators, including activators, through the use of DNA encoded library technology (DEL) and computational high-throughput screening methodologies. Top hits from both screenings against Sirt3 were evaluated according to their activity and affinity. Our best activator is more potent than the previously reported activator Honokiol. Docking studies suggest that our activators identified from virtual screening interact with Sirt3 at a site similar to Honokiol, whereas the activators identified from DEL selection interact with Sirt3 at an atypical site. Our results establish the attractiveness of these high-throughput screening technologies in identifying novel and potent Sirt3 activators and, therefore, in associated therapeutic applications.

Identifiants

pubmed: 36191547
pii: S0968-0896(22)00392-3
doi: 10.1016/j.bmc.2022.116999
pii:
doi:

Substances chimiques

Allyl Compounds 0
Biphenyl Compounds 0
Lignans 0
Phenols 0
honokiol 11513CCO0N
SIRT3 protein, human EC 3.5.1.-
Sirtuin 3 EC 3.5.1.-
Sirtuins EC 3.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116999

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Célina Reverdy (C)

Center for Protein Engineering & Drug Discovery, PMC Isochem SAS, 32 rue Lavoisier, F-91710 Vert-le-Petit, France.

Gaetan Gitton (G)

Center for Protein Engineering & Drug Discovery, PMC Isochem SAS, 32 rue Lavoisier, F-91710 Vert-le-Petit, France.

Xiangying Guan (X)

Division of Fundamental Research, Chakrabarti Advanced Technology, PMC Group Building, 1288 Route 73, Mount Laurel, NJ, USA.

Indranil Adhya (I)

Center for Protein Engineering & Drug Discovery, PMC Isochem SAS, 32 rue Lavoisier, F-91710 Vert-le-Petit, France.

Rama Krishna Dumpati (R)

Division of Computational Research, Chakrabarti Advanced Technology, Hyderabad, Telangana, India.

Samir Roy (S)

Division of Computational Research, Chakrabarti Advanced Technology, Hyderabad, Telangana, India.

Santu Chall (S)

Division of Computational Research, Chakrabarti Advanced Technology, Hyderabad, Telangana, India.

Anisha Ghosh (A)

Division of Fundamental Research, Chakrabarti Advanced Technology, PMC Group Building, 1288 Route 73, Mount Laurel, NJ, USA; Division of Computational Research, Chakrabarti Advanced Technology, Hyderabad, Telangana, India.

Gauthier Errasti (G)

Center for Protein Engineering & Drug Discovery, PMC Isochem SAS, 32 rue Lavoisier, F-91710 Vert-le-Petit, France.

Thomas Delacroix (T)

Center for Protein Engineering & Drug Discovery, PMC Isochem SAS, 32 rue Lavoisier, F-91710 Vert-le-Petit, France.

Raj Chakrabarti (R)

Center for Protein Engineering & Drug Discovery, PMC Isochem SAS, 32 rue Lavoisier, F-91710 Vert-le-Petit, France; Division of Fundamental Research, Chakrabarti Advanced Technology, PMC Group Building, 1288 Route 73, Mount Laurel, NJ, USA; Division of Computational Research, Chakrabarti Advanced Technology, Hyderabad, Telangana, India. Electronic address: raj@pmc-group.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH